Molecular Culture®
Molecular diagnostic assay for identifying bacterial species in clinical samples.
Maturity not rated
Startup · Netherlands
Inbiome
HQ Amsterdam, NetherlandsFounded 201911-50 employees
Molecular diagnostics for rapid bacterial identification.
Products1
Newest unveiled first. Open a product for its milestone timeline, components and sources.
Funding1 round · $16.0M
- Disclosed
- $16.0M
- Latest
- $16.0MSeries A · Apr 1, 2026
| Announced | Stage | Amount | Valuation | Lead investors | Other investors | Confidence |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Series A | $16.0M | — | NATO Innovation Fund, Slingshot Ventures | — | Confirmed |
- $16.0MApr 1, 2026
Totals add known amounts using recorded USD conversions where available; other currencies are shown separately. A ~ marks an estimated amount.
Sources8
Profile6
- 1
PitchBook · Supports Organization · employee range, Organization · linkedin url, Organization · x url
“employee_range: 11-50 (profile: 25)”
- 2DatabaseInbiome — hq city
Crunchbase · Supports Organization · employee range, Organization · hq city, Organization · linkedin url, Organization · x url
“employee_range: 11-50 (profile: 11-50)”
- 3
- 4
- 5DatabaseInbiome — founded year
LinkedIn · Supports Organization · employee range, Organization · founded year, Organization · linkedin url
“employee_range: 11-50 (profile: 11-50 employees)”
- 6
Products1
- 7CompanyMolecular Culture® - inbiome
Inbiome · Supports System
“Inbiome’s Molecular Culture® technique enables drastically faster and more accurate bacterial diagnostics compared to traditional culture. It is the first diagnostic test that can detect the vast majority of bacterial species in a single assay.”
Funding1
- 8
NATO Innovation Fund · Apr 1, 2026 · Supports Funding round · amount
“The USD 16 million Series A was co-led by the NATO Innovation Fund (NIF)”
Each fact on this page is attached to the sources that support it. Archived copies are linked when we keep one.